TITLE

Review: Interferon α-2b is effective for biochemical and virologic outcomes in acute hepatitis C virus infection

AUTHOR(S)
King, Paul D.
PUB. DATE
September 2002
SOURCE
ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p60
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a study that investigated the effectiveness of interferon in patients with acute hepatitis C virus infection. Interferon α-2b versus no treatment in acute hepatitis C virus infection; Information on data sources and study selection; Analysis of the effect of interferon on the biological outcomes and virologic clearance of the patients.
ACCESSION #
7519817

 

Related Articles

  • Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. Amorosa, Valerianna K.; Luetkemeyer, Anne; Kang, Minhee; Johnson, Victoria A.; Umbleja, Triin; Haas, David W.; Yesmin, Suria; Bardin, Matthew C.; Chung, Ray T.; Alston-Smith, Beverly; Tebas, Pablo; Peters, Marion G. // HIV Clinical Trials (Thomas Land Publishers Incorporated);Nov/Dec2013, Vol. 14 Issue 6, p274 

    Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study...

  • Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison, John G.; Lawitz, Eric J.; Shiffman, Mitchell L.; Muir, Andrew J.; Galler, Greg W.; McCone, Jonathan; Nyberg, Lisa M.; Lee, William M.; Ghalib, Reem H.; Schiff, Eugene R.; Galati, Joseph S.; Bacon, Bruce R.; Davis, Mitchell N.; Mukhopadhyay, Pabak; Koury, Kenneth; Noviello, Stephanie; Pedicone, Lisa D.; Brass, Clifford A.; Albrecht, Janice K.; Sulkowski, Mark S. // New England Journal of Medicine;8/6/2009, Vol. 361 Issue 6, p580 

    Background: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods: At 118 sites, patients who had HCV genotype 1...

  • IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. Estrabaud, Emilie; Appourchaux, Kevin; Bièche, Ivan; Carrat, Fabrice; Lapalus, Martine; Lada, Olivier; Martinot-Peignoux, Michelle; Boyer, Nathalie; Marcellin, Patrick; Vidaud, Michel; Asselah, Tarik // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide. The intra-hepatic level of expression of interferon stimulated genes (ISGs) and the...

  • Interferon-Free Regimens for Hepatitis C: Combine and Conquer. Martel-Laferrière, Valérie; Bichoupan, Kian; Dieterich, Douglas // BioDrugs;Apr2014, Vol. 28 Issue 2, p161 

    Since the approval of the first direct-acting antiviral agents (DAAs), treatment for hepatitis C virus (HCV) has undergone significant transformation. A new milestone in the treatment of HCV, the approval of the first interferon-free regimens, could be achieved by the end of 2013. For patients...

  • Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Monje-Agudo, P.; Castro-Iglesias, A.; Rivero-Juárez, A.; Martínez-Marcos, F.; Ortega-González, E.; Real, L.; Pernas, B.; Merchante, N.; Cid, P.; Macías, J.; Merino, M.; Rivero, A.; Mena, A.; Neukam, K.; Pineda, J. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2015, Vol. 34 Issue 10, p1929 

    It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, this hypothesis is derived from comparing different studies. The aim of this study was...

  • How to improve virological sustained response rate by interferon therapy for patients with chronic hepatitis C. Izumi, Namiki // Journal of Gastroenterology;2001, Vol. 36 Issue 4, p281 

    Editorial. Focuses on ways to improve the virological sustained response (VSR) rate to interferon therapy of patients with chronic hepatitis C. Brief information on VSR; Factors associated with VSR; Modification in interferon administration.

  • An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Ogawa, Eiichi; Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Satoh, Takeaki; Maruyama, Toshihiro; Nakamuta, Makoto; Kotoh, Kazuhiro; Azuma, Koichi; Dohmen, Kazufumi; Shimoda, Shinji; Hayashi, Jun // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2012, Vol. 18 Issue 5, p689 

    The aim of this large-scale analysis was to assess the effect of 48-week pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) therapy on virological relapse by patients infected with hepatitis C virus (HCV) genotype 1. The relationship between virological relapse and the dose of...

  • Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías, Juan; Del Valle, José; Rivero, Antonio; Mira, José A.; Camacho, Ángela; Merchante, Nicolás; Pérez-Camacho, Inés; Neukam, Karin; Rivero-Juárez, Antonio; Mata, Rosario; Torre-Cisneros, Julián; Pineda, Juan A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2204 

    Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.

  • Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. Haseltine, Eric; Kimko, Holly; Luo, Haobin; Tolsma, John; Bartels, Doug; Kieffer, Tara; Garg, Varun // Journal of Pharmacokinetics & Pharmacodynamics;Dec2015, Vol. 42 Issue 6, p681 

    Viral dynamic modelling has proven useful for designing clinical studies and predicting treatment outcomes for patients infected with the hepatitis C virus. Generally these models aim to capture and predict the on-treatment viral load dynamics from a small study of individual patients. Here, we...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics